Modulation of anabolic and catabolic responses via a porous polymer scaffold manufactured using thermally induced phase separation

European Cells and Materials

Volumn 25, Issue , 2012, Pages 190-203

  Yu, Nicole Y C ^a,b   Schindeler, Aaron ^a,b   Peacock, Lauren ^a   Mikulec, Kathy ^a   Fitzpatrick, Jane ^c   Ruys, Andrew J ^b   Cooper White, Justin J ^c   Little, David G ^a,b  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Biodegradable polymer scaffold; Bisphosphonate; Bone morphogenetic protein; Bone tissue engineering; rhBMP 2; Thermally induced phase separation; Zoledronic acid

Indexed keywords

HYDROXYAPATITE; MOLECULAR SCAFFOLD; POLYGLACTIN; POLYLACTIC ACID; POROUS POLYMER; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; BONE MORPHOGENETIC PROTEIN 2; IMIDAZOLE DERIVATIVE; LACTIC ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID POLYGLYCOLIC ACID COPOLYMER; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; POLYMER; RECOMBINANT HUMAN BONE MORPHOGENETIC PROTEIN-2; RECOMBINANT PROTEIN; TISSUE SCAFFOLD; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIODEGRADATION; BIOSYNTHESIS; BONE DENSITY; BONE DISEASE; BONE IMPLANT; BONE MASS; CATABOLISM; COMPRESSIVE STRENGTH; CONTROLLED STUDY; DRUG DELIVERY DEVICE; ECTOPIC BONE FORMATION; FEMALE; IN VIVO STUDY; MOUSE; NANOFABRICATION; NONHUMAN; OSSIFICATION; OUTCOME ASSESSMENT; PHASE SEPARATION; PROCESS OPTIMIZATION; TISSUE ENGINEERING; YOUNG MODULUS; ANIMAL; BONE; BONE PROSTHESIS; BONE REGENERATION; C57BL MOUSE; CHEMISTRY; DRUG EFFECT; IMPLANT; PHYSIOLOGY; POROSITY; RADIOGRAPHY;

ANIMALS; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE MORPHOGENETIC PROTEIN 2; BONE REGENERATION; BONE SUBSTITUTES; COMPRESSIVE STRENGTH; DIPHOSPHONATES; DURAPATITE; FEMALE; IMIDAZOLES; IMPLANTS, EXPERIMENTAL; LACTIC ACID; MICE; MICE, INBRED C57BL; POLYGLYCOLIC ACID; POLYMERS; POROSITY; RECOMBINANT PROTEINS; TISSUE ENGINEERING; TISSUE SCAFFOLDS; TRANSFORMING GROWTH FACTOR BETA;

MLCS; MLOWN;

EID: 84878399537     PISSN: 14732262     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Athanasiou KA, Niederauer GG, Agrawal CM (1996) Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid/ polyglycolic acid copolymers. Biomaterials 17: 93-102.
2. Belfrage O, Flivik G, Sundberg M, Kesteris U, Tägil M (2011) Local treatment of cancellous bone grafts with BMP-7 and zoledronate increases both the bone formation rate and bone density. Acta Orthopaedica 82: 228-233.
3. Bouxsein M, Blake C, Luppen C, Cooper J, Wozney J, Seeherman H (2001) Interaction between systemic bisphosphonate therapy and bone formation induced by local delivery of rhBMP-2 in non-human primates. J Bone Miner Res 16: S234.
4. Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Müller R (2010) Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J J Bone Miner Res 25: 1468-1486.
5. Calandrelli L, Immirzi B, Malinconico M, Volpe MG, Oliva A, Della Ragione F (2000) Preparation and characterisation of composites based on biodegradable polymers for in vivo application. Polymer 41: 8027.
6. Calandrelli L, Immirzi B, Malinconico M, Luessenheide S, Passaro I, Pasquale R, Oliva A (2004) Natural and synthetic hydroxyapatite filled PCL: mechanical properties and biocompatibility analysis. J Bioact Compat Polym 19: 301-313.
7. Cao Y, Croll TI, Cooper-White JJ, O'Connor AJ, Stevens GW (2004) Production and surface modification of polylactide-based polymeric scaffolds for soft tissue engineering. In: Biopolymer methods in tissue engineering (Hollander AP, Hatton PV, eds), Humana Press, Totowa, NJ, pp 87-111.
8. Cao Y, Croll TI, O'Connor AJ, Stevens GW, Cooper-White JJ (2006a) Systematic selection of solvents for the fabrication of 3D combined macro-and microporous polymeric scaffolds for soft tissue engineering. J Biomater Sci Polymer Ed 17: 369-402.
9. Cao Y, Mitchell G, Messina A, Price L, Thompson E, Penington A, Morrison W, O'Connor A, Stevens G, Cooper-White J (2006b) The influence of architecture on degradation and tissue ingrowth into three-dimensional poly(lactic-co-glycolic acid) scaffolds in vitro and in vivo. Biomaterials 27: 2854-2864.
10. Causa F, Netti P, Ambrosio L, Ciapetti G, Baldini N, Pagani S, Martini D, Giunti A (2006) Poly-e-caprolactone/ hydroxyapatite composites for bone regeneration: In vitro characterization and human osteoblast response. J Biomed Mater Res 76A: 151-162.
11. Chen W-J, Jingushi S, Hirata G, Matsumoto Y, Iwamoto Y (2004) Intramuscular bone inducation by the simultaneous administration of recombinant human bone morphogenetic protein 2 and bisphosphonate for autobone graft. Tissue Eng 10: 1652-1661.
12. Chen W-J, Jingushi S, Jingushi K, Iwamoto Y (2006) In vivo banking for vascularized autograft bone by intramuscular inoculation of recombinant human bone morphogenetic protein-2 and β-tricalcium phosphate. J Orthop Sci 11: 283-288.
13. Choi J-Y, Kim H-J, Lee Y-C, Cho B-O, Seong H-S, Cho M, Kim S-G (2007) Inhibition of bone healing by pamidronate in calvarial bony defects. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 103: 321-328.
14. Coathup MJ, Blunn GW, Flynn N, Williams C, Thomas NP (2001) A comparison of bone remodelling around hydroxyapatite-coated, porous-coated and grit-blasted hip replacements retrieved at post-mortem. J Bone Joint Surg Br 83-B: 118-123.
15. DeLustro F, Dasch J, Keefe J, Ellingsworth L (1990) Immune responses to allogeneic and xenogeneic implants of collagen and collagen derivatives. Clin Orthop Relat Res 260: 263-279.
16. Geesink RGT, Hoefnagels NHM, Bulstra SK (1999) Osteogenic activity of OP-1 bone morphogenetic protein (BMP-7) in a human fibular defect. J Bone Joint Surg Br 81-B: 710-718.
17. Giannoudis PV, Einhorn TA, Marsh D (2007) Fracture healing: The diamond concept. Injury 38: S3.
18. Gong L, Hoshi K, Ejiri S, Nakajima T, Shingaki S, Ozawa H (2003) Bisphosphonate incadronate inhibits maturation of ectopic bone induced by recombinant human bone morphogenetic protein 2. J Bone Mineral Metab 21: 5-11.
19. Guillemin G, Meunier A, Dallant P, Christel P, Pouliquen JC, Sedel L (1989) Comparison of coral resorption and bone apposition with two natural corals of different porosities. J Biomed Mater Res 23: 765-779.
20. Harding AK, Aspenberg P, Kataoka M, Bylski D, Tägil M (2008) Manipulating the anabolic and catabolic response in bone graft remodeling: Synergism by a combination of local BMP-7 and a single systemic dosis of zoledronate. J Orthop Res 26: 1245-1249.
21. Hollister SJ (2005) Porous scaffold design for tissue engineering. Nat Mater 4: 518-524.
22. Idris A, Rojas J, Greig I, Van't Hof R, Ralston S (2008) Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro. Calcif Tissue Int. 82: 191-201.
23. Itoh K, Udagawa N, Katagiri T, Iemura S, Ueno N, Yasuda H, Higashio K, Quinn JMW, Gillespie MT, Martin TJ, Suda T, Takahashi N (2001) Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-kB Ligand. Endocrinology 142: 3656-3662.
24. Jack KS, Velayudhan S, Luckman P, Trau M, Grøndahl L, Cooper-White J (2009) The fabrication and characterization of biodegradable HA/PHBV nanoparticle-polymer composite scaffolds. Acta Biomaterialia 5: 2657-2667.
25. Jakobsen T, Baas J, Bechtold JE, Elmengaard B, Soballe K (2007) Soaking morselized allograft in bisphosphonate can impair implant fixation. Clin Orthopaed Rel Res 463: 195-201.
26. Jakobsen T, Baas J, Bechtold J, Elmengaard B, Søballe K (2010) The effect of soaking allograft in bisphosphonate: A pilot dose-response study. Clin Orthopaed Rel Res 468: 867-874.
27. Jeppsson C, Åstrand J, Tägil M, Aspenberg P (2003) A combination of bisphosphonate and BMP additives in impacted bone allografts. Acta Orthopaed Scand 74: 483-489.
28. Jung Y, Kim S-S, Kim Y, Kim S-H, Kim B-S, Kim S, Choi C, Kim S (2005) A poly(lactic acid)/calcium metaphosphate composite for bone tissue engineering. Biomaterials 26: 6314-6322.
29. Kaneko H, Arakawa T, Mano H, Kaneda T, Ogasawara A, Nakagawa M, Toyama Y, Yabe Y, Kumegawa M, Hakeda Y (2000) Direct stimulation of osteoclastic bone resorption by bone morphogenetic protein (BMP)-2 and expression of BMP receptors in mature osteoclasts. Bone 27: 479.
30. Kato M, Toyoda H, Namikawa T, Hoshino M, Terai H, Miyamoto S, Takaoka K (2006) Optimized use of a biodegradable polymer as a carrier material for the local delivery of recombinant human bone morphogenetic protein-2 (rhBMP-2). Biomaterials 27: 2035.
31. Kim H-W, Knowles J, Kim H-E (2004) Effect of biphasic calcium phosphates on drug release and biological and mechanical properties of poly (epsilon-caprolactone) composite membranes. J Biomed Mater Res 70A: 467-479.
32. Little D, McDonald M, Bransford R, Godfrey C, Amanat N (2005) Manipulation of the anabolic and catabolic responses with OP-1 and zoledronic acid in a rat critical defect model. J Bone Miner Res 20: 2044-2052.
33. Little DG, Ramachandran M, Schindeler A (2007) The anabolic and catabolic responses in bone repair. J Bone Joint Surg Br 89-B: 425-433.
34. Liu X, Ma PX (2004) Polymeric scaffolds for bone tissue engineering. Ann Biomed Eng 32: 477-486.
35. Marx RE, Sawatari, Y., Fortin, M. & Broumand, V. (2005) Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63: 1567-1575.
36. Middleton JC, Tipton AJ (2000) Synthetic biodegradable polymers as orthopedic devices. Biomaterials 21: 2335-2346.
37. Mikos AG, Thorsen AJ, Czerwonka LA, Bao Y, Langer R, Winslow DN, Vacanti JP (1994) Preparation and characterization of poly(l-lactic acid) foams. Polymer 35: 1068-1077.
38. Mönkkönen J, Similä J, Rogers MJ (1998) Effects of tiludronate and ibandronate on the secretion of proinflammatory cytokines and nitric oxide from macrophages in vitro. Life Sci 62: 95-102.
39. Mooney DJ, Kaufmann PM, Sano K, McNamara KM, Vacanti JP, Langer R (1994) Transplantation of hepatocytes using porous, biodegradable sponges. Transplant Proc 26: 3425-3426.
40. Olsen D, Yang C, Bodo M, Chang R, Leigh S, Baez J, Carmichael D, Perälä M, Hämäläinen E, Jarvinen M, Polarek J (2003) Recombinant collagen and gelatin for drug delivery. Adv Drug Deliv Rev 55: 1547-1567.
41. Pradhan B, Bae H, Dawson E, Patel V, Delamarter R (2006) Graft resorption with the use of bone morphogenetic protein: lessons from anterior lumbar interbody fusion using femoral ring allografts and recombinant human bone morphogenetic protein-2. Spine (Phila Pa 1976) 31: E377-384.
42. Rezwan K, Chen QZ, Blaker JJ, Boccaccini AR (2006) Biodegradable and bioactive porous polymer/ inorganic composite scaffolds for bone tissue engineering. Biomaterials 27: 3413-3431.
43. Rizzi S, Heath D, Coombes A, Bock N, Textor M, Downes S (2001) Biodegradable polymer/hydroxyapatite composites: Surface analysis and initial attachment of human osteoblasts. J Biomed Mater Res 55: 475-486.
44. Ruys AJ, Sorrell CC, Brandwood A, Milthorpe BK (1995) Hydroxyapatite sintering characteristics: correlation with powder morphology bv high-resolution microscopy. J Mater Sci Lett 14: 744-747.
45. Seeherman H, Li J, Blake C, Gavin D, Wozney J, Bouxsein M (2001) Histology indicates bisphosphonate limits transient resorption without decreasing bone induction in nonhuman primate core defects treated with rhBMP-2/ACS. J Bone Miner Res 16: S438.
46. Seshima H, Yoshinari M, Takemoto S, Hattori M, Kawada E, Inoue T, Oda Y (2006) Control of bisphosphonate release using hydroxyapatite granules. J Biomed Mater Res B: Appl Biomater 78B: 215-221.
47. Shi X, Wang Y, Ren L, Gong Y, Wang D-A (2009) Enhancing alendronate release from a novel PLGA/ Hydroxyapatite microspheric system for bone repairing applications. Pharm Res 26: 422-430.
48. Smith EJ, McEvoy A, Little DG, Baldock PA, Eisman JA, Gardiner EM (2004) Transient retention of endochondral cartilaginous matrix with bisphosphonate treatment in a long-term rabbit model of distraction osteogenesis. J Bone Miner Res 19: 1698-1705.
49. Tägil M, Aspenberg P, Åstrand J (2006) Systemic zoledronate precoating of a bone graft reduces bone resorption during remodeling. Acta Orthop 77: 23-26.
50. Thiébaud D, Sauty A, Burckhardt P, Leuenberger P, Sitzler L, Green JR, Kandra A, Zieschang J, Ibarra de Palacios P (1997) An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tissue Int 61: 386-392.
51. Wei G, Ma PX (2004) Structure and properties of nano-hydroxyapatite/polymer composite scaffolds for bone tissue engineering. Biomaterials 25: 4749-4757.
52. Wolff J (1892) Das Gesetz der Transformation der Knochen (The Law of Bone Transformation) (English translation published by Springer-Verlag, Berlin, in 1986).
53. Yu H, Wooley P, Yang S-Y (2009) Biocompatibility of Poly-epsilon-caprolactone-hydroxyapatite composite on mouse bone marrow-derived osteoblasts and endothelial cells. J Orthopaed Surg Res 4: 5.
54. Yu NYC, Schindeler A, Little DG, Ruys AJ (2010a) Biodegradable poly(α-hydroxy acid) polymer scaffolds for bone tissue engineering. J BiomedMater Res B: Appl Biomater 93B: 285-295.
55. Yu NYC, Schindeler A, Peacock L, Mikulec K, Baldock PA, Ruys AJ, Little DG (2010b) In vivo local co-delivery of recombinant human bone morphogenetic protein-7 and pamidronate via poly-D, L-lactic acid. Eur Cell Mater 20: 431-442.
56. Yu NYC, Schindeler A, Tägil M, Ruys A, Little D (2012) Use of BMPs and bisphosphonates in improving bone fracture healing. Front Biosci (Elite Ed) 4: 2647-2653.
57. Carragee EJ, Hurwitz EL, Weiner BK (2011) A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J 11: 471-491.